The Schall Law Firm has announced a class action lawsuit against SES AI Corporation (NYSE: SES) for alleged securities fraud, encouraging investors who purchased securities between January 29, 2025, and March 4, 2026, to contact them before June 26, 2026. The lawsuit claims SES made false and misleading statements about the potential results of deals with companies lacking substantial operations and misled the market by purchasing services in exchange for its Molecular Universe platform. Investors are urged to join the case to recover their losses.

Apollo Global Management has decided not to proceed with a firm offer for British thermal processing services company Bodycote, ending talks over a £1.52 billion ($2.04 billion) proposal. This decision means Apollo is restricted from making another approach for six months under British takeover rules, although the company expressed continued high regard for Bodycote. Bodycote's shares had previously surged on news of Apollo's conditional all-cash bid.

This article outlines five structural risks for AMD stock over the next six months, urging investors to look beyond the bull narrative. These risks include potential hyperscaler CapEx "digestion," drag from legacy gaming and client segments, Nvidia Blackwell performance solidifying market lock-in, escalation of US AI chip export controls to China, and valuation compression due to "higher for longer" interest rates. The piece emphasizes the importance of a concrete framework to monitor these risks for capital protection.

Syensqo SA received a transparency notification from BlackRock Inc. indicating that BlackRock's direct voting rights in Syensqo crossed the 3% threshold. The notification states that BlackRock Inc. now holds 3.07% direct voting rights and 0.89% equivalent financial instruments, totaling 3.96% after transactions on June 02, 2026. This disclosure was made in accordance with Belgian transparency legislation.

Gilead Sciences applauds the proactive steps taken by the Government of South Africa and the Global Fund to expedite access to lenacapavir, a long-acting medication for HIV prevention. This initiative is crucial for expanding HIV prevention options in South Africa, which currently bears the largest HIV burden globally. Gilead is committed to ensuring broad, equitable access to lenacapavir through partnerships, voluntary licensing agreements, and support for local manufacturing, aiming to significantly reduce new HIV infections.

Solidion Technology Inc. announced a breakthrough in lithium metal battery technology with a patented anode protection platform, protected by over 30 patents. This technology aims to overcome key commercialization hurdles for ultra-high energy lithium metal batteries, particularly for space applications like satellites and LEO-based AI data centers. The platform also has "down-to-earth" applications for electric vehicles, drones, and AI data center UPS systems, reinforcing domestic supply chain security with its U.S.-based patent portfolio.

ADAR1 Capital Management, LLC and Daniel Schneeberger collectively purchased approximately $2.18 million worth of Rallybio Corp (NASDAQ:RLYB) common stock on May 4 and 5, 2026. This insider buying activity occurs as RLYB trades near its 52-week high after a 505% gain over the past year, though InvestingPro analysis suggests the stock is overvalued. The purchases involved a total of 155,905 shares at prices ranging from $13.8600 to $14.0000.

Dharmendra Kumar Sinha, EVP at Rackspace Technology, sold 48,099 shares worth $267,430 to cover tax obligations from vested restricted stock units. This sale was made under a Rule 10b5-1 plan, and he still holds over 3.3 million shares. The company recently reported mixed Q1 2026 earnings but is focusing on AI and cloud services through partnerships like the one with AMD, influencing its stock performance.

The Federal Energy Regulatory Commission (FERC) has approved Constellation Energy’s request to fast-track the reopening of the Three Mile Island nuclear power plant in Pennsylvania. The plant is expected to be back online next year to supply power to nearby Microsoft data centers, addressing rising electricity costs in the region. This accelerates a prior timeline, with Microsoft having already committed to a 20-year contract for the plant's electricity.

Revolution Medicines, a Redwood City company, has developed an experimental drug called daraxonrasib, a pill to treat pancreatic cancer. Clinical trials showed promising results, doubling the survival rates from 6.5 months with chemotherapy to over 13 months with the new pill. Due to these promising outcomes, the FDA is fast-tracking the drug's approval process.